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Abstract  
The currently available antiepileptic drugs are typically administered via oral or 
intravenous (IV) routes which commonly exhibit high systemic distribution into non-
targeted tissues, leading to peripheral adverse effects and limited brain uptake. In order 
to improve the efficacy and tolerability of the antiepileptic drug therapy, alternative 
administration strategies have been investigated. The purpose of the present study was 
to assess the pharmacokinetics of carbamazepine administered via intranasal (IN) and 
IV routes to mice, and to investigate whether a direct transport of the drug from nose to 
brain could be involved. The similar pharmacokinetic profiles obtained in all matrices 
following both administration routes indicate that, after IN delivery, carbamazepine 
reaches quickly and extensively the bloodstream, achieving the brain predominantly via 
systemic circulation. However, the uneven biodistribution of carbamazepine through the 
brain regions with higher concentrations in the olfactory bulb and frontal cortex 
following IN instillation, in comparison with the homogenous brain distribution pattern 
after IV injection, strongly suggests the involvement of a direct transport of 
carbamazepine from nose to brain. Therefore, it seems that IN delivery represents a 
suitable and promising alternative route to administer carbamazepine not only for the 
chronically use of the drug but also in emergency conditions.    
 
Keywords: Carbamazepine, Intranasal administration, Pharmacokinetics, Nose-to-brain 
drug delivery, Brain distribution, Mice  
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1. Introduction 
Epilepsy is one of the most common and devastating neurological disorders 
which is estimated to have a worldwide prevalence of about 0.5-1% (White, 2003). 
There are several antiepileptic drugs currently available to control and suppress 
seizures. However, despite the ongoing development of new pharmacological therapies, 
more than 30% of the patients do not become seizure free mainly due to the 
pharmacoresistance phenomena (Weaver and Pohlmann-Eden, 2013). Moreover, 
conventional antiepileptic drug administration via either oral or intravenous (IV) routes 
commonly exhibits high systemic drug distribution into central nervous system (CNS) 
and non-targeted tissues which can potentiate the occurrence of drug-drug interactions 
and undesirable side effects that range from a CNS impairment (e.g. somnolence, 
dizziness and ataxia) to more severe peripheral pathological conditions such as skin 
reactions and hematologic, hepatic and renal dysfunctions (Toledano and Gil-Nagel, 
2008). 
Arguably, the delivery of drugs to the CNS remains a great challenge owing to 
the strict structural and functional blood brain barrier (BBB) (Gabathuler, 2010). Thus, 
over the last decades, different strategies have been attempted in order to circumvent the 
BBB and to deliver drugs efficiently into the brain for therapeutic and diagnostic 
applications (Gabathuler, 2010; Illum, 2000). In fact, the development of new 
alternative drug delivery methods could enhance the efficacy and minimize the toxicity 
of antiepileptic drugs, thereby improving their therapeutic index (Fisher and Ho, 2002). 
The intranasal (IN) administration has long been widely used for the symptomatic relief 
and treatment of local nasal dysfunctions, but recently, it has received a great attention 
as a convenient and reliable route for the systemic administration of drugs (Grassin-
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Delyle et al., 2012). Nevertheless, assuming the olfactory region as a unique direct 
connection between the nose and the brain, an increasing interest has been posed on the 
potential of the IN route for the delivery of therapeutic agents directly to the CNS 
bypassing the BBB (Illum, 2004; Vyas et al., 2005). Indeed, IN administration 
represents an attractive alternative to parenteral and oral routes since, in addition to be 
non-invasive, it also avoids gastrointestinal and hepatic first-pass metabolism. The 
rapid-onset of action and the preferential delivery of drugs to the brain also enable the 
IN route to be successfully applied in the management of emergency situations (Li et 
al., 2000; Wolfe and Bernstone, 2004). 
 Carbamazepine (Figure 1) is one of the first-line antiepileptic drugs most 
commonly prescribed despite its narrow therapeutic window, complex pharmacokinetic 
profile, potential for drug interactions and severe side effects (Gerlach and Krajewski, 
2010; Neels et al., 2004; Patsalos et al., 2008). Currently, carbamazepine is only 
available in tablet or suspension oral dosage forms due to its poor water solubility that 
prevents its incorporation in therapeutic dosages in aqueous solutions for IV injection. 
Following oral administration, the absorption of carbamazepine is relatively slow, 
erratic and formulation dependent (Landmark et al., 2012); its oral bioavailability is 
within the range 75-85% (Landmark et al., 2012) and the time to reach peak 
concentration in plasma is approximately 4-8 h post-dosing but it may be delayed by as 
much as 24 h with high doses (Neels et al., 2004). Furthermore, carbamazepine 
undergoes extensive hepatic metabolism and considerable enzymatic induction that 
result in unpredictable plasmatic fluctuations and unexpected clearance increments 
which demand successive dose adjustments (Patsalos et al., 2008; Tomson, 1987). 
Taking into account all those pharmacokinetic limitations of carbamazepine oral 
administration, we do believe that this antiepileptic drug is a promising candidate to be 
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administered by the IN route. A prompt and efficient IN drug delivery to the brain may 
decrease the systemic exposure, improving both efficacy and tolerability profiles. The 
opportunity to control seizures by reducing the dose makes IN administration of 
carbamazepine a valuable approach for long-term treatment of epilepsy. Likewise, it 
could also give an attractive advantage in the management of acute and severe 
convulsive seizure episodes. In fact, IV administration of benzodiazepines is the first-
line option for the treatment of status epilepticus (Lockey, 2002; Manno, 2011); 
however, it is generally associated with hypotension, cardiac dysrhythmia and 
respiratory failure. Furthermore, IV injection requires sterile equipment and skilled 
personnel which often makes it impractical and inconvenient to use outside the hospital 
setting. Bearing in mind that quick cessation of the seizures is essential to prevent 
serious neurological damages, a rapid access and a high brain bioavailability of 
carbamazepine administered via IN route may probably contribute to its recognition as a 
viable alternative to IV administration of the drugs used in emergency conditions. 
 Interestingly, IN administration of carbamazepine has already been studied in 
rats by Barakat and collaborators (2006), reporting high levels of drug penetration in the 
brain solely based on the analysis of plasma and whole brain homogenates. Therefore, a 
comprehensive pharmacokinetic characterization of intranasal carbamazepine and its 
active metabolite mainly responsible for the toxic effects, carbamazepine-10,11-epoxide  
(Figure 1), is lacking. In this context, plasma, brain and liver levels of both 
carbamazepine and carbamazepine-10,11-epoxide, were, in this study, determined 
following IN and IV administrations to mice, and the corresponding pharmacokinetic 
profiles were assessed and compared. Additionally, in order to establish a more 
sustained basis for an hypothetic direct transport of the drug from nose to brain via the 
olfactory pathway, carbamazepine concentrations were also determined in different 
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brain regions and the rostral-caudal brain distribution of the drug was studied following 
the two routes of administration considered.   
 
2. Materials and methods 
2.1. Chemicals and reagents 
 Carbamazepine and 10,11-dihydrocarbamazepine, used as internal standard (IS), 
as well as Pluronic F-127 and propylene glycol were all purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Carbopol 974P was kindly supplied from Lubrizol (Wickliffe, 
OH, USA). Methanol and acetonitrile of high performance liquid chromatography 
(HPLC) gradient grade were acquired from Fisher Scientific (Leicestershire, UK) and 
Lab-Scan (Sowinskiego, Poland) respectively. Ultrapure water (HPLC grade, 
18.2MΩ.cm) was prepared by means of a Milli-Q water apparatus from Millipore 
(Milford, MA, USA). Ethyl acetate was obtained from Fisher Scientific (Leicestershire, 
UK). Sodium dihydrogen phosphate dihydrate, di-sodium hydrogen phosphate 
dihydrate and hydrochloric acid fuming 37%, all used to prepare 0.1 M sodium 
phosphate buffer pH=5.0, were purchased from Merck KGaA (Darmstadt, Germany). 
Ketamine (Imalgene 1000®, 100 mg/ml) and xylazine (Vetaxilaze 20®, 20 mg/ml) were 
commercially acquired. 
 
2.2. Animals 
Adult male CD-1 mice aged between 6 and 7 weeks and weighing 30-40 g were 
obtained from local certified animal facilities (Faculty of Health Sciences of the 
University of Beira Interior, Covilhã, Portugal). Mice were housed under controlled 
environmental conditions (12 h light/dark cycle, at 20±2°C and relative humidity 
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50±5%) with free access to tap water and standard rodent diet (4RF21, Mucedola, Italy). 
All the experiments involving animals and their care were conducted in conformity with 
the international regulations of the European Directive (2010) regarding the protection 
of laboratory animals used for scientific purposes (2010/63/EU), and the experimental 
procedures employed were reviewed by the Portuguese Veterinary General Division. 
 
2.3. Preparation of carbamazepine formulations 
For IN administration, carbamazepine was previously dissolved in ethanol at the 
concentration of 20 mg/ml. Then 50 µl of this ethanolic solution was incorporated in 
950 µl of a thermoreversible nasal gel so that the final drug concentration was 1 mg/ml 
and the total percentage of ethanol in the formulation was equivalent to 5%. 
Thermoreversible gel was prepared using the cold method described by Schmolka 
(1972). Briefly, 1.8 g of Pluronic F-127 (PF-127) was slowly added to 10 ml of distilled 
cold water (5-10°C), under gentle magnetic stirring, to achieve an efficient hydration of 
the flakes and then, the mixture was left at 4°C overnight to attain a complete 
dissolution of the polymer (18% PF-127, w/v). Afterwards, according to the technique 
employed by Badgujar and co-workers (2010), the mucoadhesive polymer Carbopol 
974P (C-974P) was gradually dispersed in the prepared PF-127 solution with 
continuous agitation, until a final concentration of 0.2% w/v was reached. At this point, 
a nasal hydrogel formulation composed by 18% PF-127 and 0.2% C-974P was 
obtained, exhibiting thermo-sensible properties. In fact, PF-127 is a triblock copolymer 
of poly(ethylene oxide) and poly(propylene oxide) units that is fluid at or below room 
temperature; however it forms a gel as the temperature increases, as a consequence of 
the micelle packing disorder-order transition phenomenon (Swamy and Abbas, 2012). 
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This thermo-sensible behavior makes the final formulation suitable for gelation within 
the nasal cavity, providing a sustained residence of the drug at the absorption site. 
For the IV administration, a carbamazepine solution was prepared as a mixture of 
propylene glycol-physiologic saline (0.9% NaCl)-ethanol (5:3:2, v/v/v) at a final drug 
concentration of 0.1 mg/ml. 
  
2.4. IN and IV administrations 
Before carbamazepine dosing, mice were always anaesthetized with an 
intraperitoneal injection of a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg) 
and kept in a heated environment to maintain the body temperature. 
Carbamazepine was intranasally and intravenously administered at the dose of 
0.4 mg/kg. For IN administration, mice were placed on one side and 12 µl of the nasal 
gel per 30 g of mice body weight were instilled using a polyurethane tube (24G x 19 
mm) attached to a microliter syringe. The tube was inserted about 10 mm deep into one 
of the nares, enabling the delivery of the formulation towards the roof of the nasal 
cavity. IV administration of carbamazepine (0.4 mg/kg) was performed by injection via 
the lateral tail vein (120 µl per 30 g body weight) using an appropriate syringe.  
 
2.5. Pharmacokinetic studies 
 Mice were randomly divided into two experimental groups of 40 animals each. 
One of the groups received IN formulation whereas the other group was treated with the 
IV dosage form. At predetermined time points (5, 10, 15, 30, 45, 60, 90, 120, 180 and 
240 min) after carbamazepine dosing (4 animals per time point, n = 4), the mice were 
sacrificed by cervical dislocation followed by decapitation and the blood was 
  
9 
 
immediately collected into heparinised tubes while brain and liver tissues were quickly 
removed and weighed. Blood samples were centrifuged at 4°C and 4000 rpm for 10 min 
to obtain plasma supernatants that were stored at -30°C until analysis. Mice brain and 
liver tissues were homogenized with 0.1 M sodium phosphate buffer pH 5.0 (4 ml per 
gram of tissue) using a THOMAS® Teflon pestle tissue homogenizer. Tissue 
homogenates were centrifuged at 4800 rpm for 15 min (4°C) and the resultant 
supernatants were also frozen at -30°C until analysis. 
 
2.6. Brain biodistribution studies  
 Mice were divided at random into two experimental groups (20 animals each). 
The animals were treated with carbamazepine (0.4 mg/kg) using the IN or IV 
formulations. After administration, mice were sacrificed at 5, 10, 15, 30 and 60 min post 
dosing (n = 4). Blood samples were taken and plasma was separated as described above. 
Brains were removed and carefully dissected with the help of a scalpel into three 
different regions: olfactory bulb, frontal cortex and the remaining portion of the brain. 
The remaining portion of the brain was homogenized and centrifuged in accordance to 
the procedure used for brain and liver tissues, while olfactory bulb and frontal cortex 
specimens, regardless of the weight, were homogenized with 1 ml of phosphate buffer 
using an ULTRA-TURRAX® device and centrifuged at 4°C for 15 min at 13.400 rpm. 
The resultant homogenate supernatants were conveniently packaged and stored at -30°C 
until analysis. 
 
2.7. Drug analysis 
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Plasma and tissue (brain and liver) concentrations of carbamazepine and 
carbamazepine-10,11-epoxide were determined by using a solid-phase extraction 
procedure followed by a reversed-phase high performance liquid chromatography 
(HPLC) analysis, according to the method previously developed and fully validated by 
Fortuna et al. (2010) with slight modifications. 
Briefly, aliquots of plasma (200 µl), brain (500 µl) and liver (250 µl) 
homogenate supernatants were added to an appropriate volume of 0.1 M sodium 
phosphate buffer (pH 5.0) to make a total of 1 ml sample amount. Regarding the 
matrices of brain specified regions, 1 ml of both olfactory bulb and frontal cortex 
homogenate supernatants were used. All the samples were spiked with 10 µl of the 
methanolic IS working solution (200 µg/ml for all matrices excluding for the olfactory 
bulb, which was 100 µg/ml). After vortex mixed, samples were loaded into Waters 
Oasis® HLB cartridges [30 mg of hydrophilic-lipophilic-balanced (HLB) sorbent, 1 ml 
of capacity, from Milford, MA, USA], which were previously conditioned with 1 ml of 
methanol, 1 ml of acetonitrile and 1 ml of water-acetonitrile (95:5, v/v). Upon sample 
elution, the loaded cartridges were submitted to -30 kPa and washed four times with 1 
ml of water followed by four more times with 1 ml of water-methanol (90:10, v/v). 
After drying the cartridge under airflow for 5 min, the drugs were eluted with 1 ml of 
ethyl acetate applying a gentle vacuum. The eluates were then evaporated to dryness at 
45°C under moderate nitrogen stream and reconstituted with 100 µl of mobile phase by 
vortexing and ultrasonication. Finally, an aliquot of 20 µl (plasma, brain, liver and 
frontal cortex) or 40 µl (olfactory bulb) of each reconstituted extracts was injected into 
the chromatographic system for analysis.  
The HPLC analysis was carried out on a Shimadzu liquid chromatographic 
system equipped with a GDU-20A5 degasser, a SIL-20AHT autosampler, a CTO-10ASVP 
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column oven and a SPD-M20A diode array detector, all from Shimadzu Corporation 
(Kyoto, Japan). Data acquisition and instrumentation control were achieved by means of 
LCsolution software (Shimadzu Corporation, Kyoto, Japan). Chromatographic 
separation was performed at 40°C on a reversed-phase LiChroCART® Purospher Star® 
C18 column (55 mm x 4 mm, 3 µm; Merck KGaD), using an isocratic elution with a 
mobile phase consisting of water-methanol-acetonitrile (64:30:6, v/v/v) pumped at a 
flow rate of 1 ml/min. Carbamazepine and carbamazepine-10,11-epoxide were detected 
at the wavelength of 235 nm and the total running time was set at 15 min. The main 
partial validation parameters of the analytical method employed were in agreement with 
the international guidelines (FDA, 2001; EMA, 2011) and are summarized in Table 1.  
 
2.8. Pharmacokinetic analysis 
The maximum peak concentration (Cmax) in plasma and tissues of carbamazepine 
and its main metabolite (carbamazepine-10,11-epoxide) and the corresponding time to 
reach Cmax (tmax) were directly derived from the experimental data obtained. The 
remaining pharmacokinetic parameters were estimated based on the mean concentration 
values (n = 4) determined at each time point by a non-compartmental pharmacokinetic 
analysis employing the WinNonlin® version 5.2 (Pharsight Co, Mountain View, CA, 
USA). The pharmacokinetic parameters evaluated were the area under the drug 
concentration time-curve (AUC) from time zero to the time of the last quantifiable drug 
concentration (AUCt) which was calculated by the linear trapezoidal rule; the AUC 
from time zero to infinite (AUCinf) that was calculated from AUCt + (Clast/kel), where 
Clast is the last quantifiable concentration and kel is the apparent elimination rate constant 
estimated by log-linear regression of the terminal segment of the concentration-time 
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profile; the percentage of AUC extrapolated from tlast to infinity [AUCextrap(%)], where 
tlast is the time of the Clast; the apparent terminal elimination half-life (t1/2el), and the 
mean residence time (MRT).  
 The absolute bioavailability (F) of carbamazepine after IN administration was 
calculated as follows (Eq. 1): 
        (Eq. 1) 
where AUCinf IN and AUCinf IV are the areas under the drug concentration-time curves 
from time zero to infinity following IN and IV administration, respectively; DoseIV and 
DoseIN are the values of the carbamazepine dosage (mg/kg) given by IV and IN route to 
mice.  
 In order to assess brain targeting efficiency of nasally delivered carbamazepine, 
the drug targeting efficiency (DTE) index was calculated (Wang et al., 2003). DTE 
index represents the brain-to-plasma partitioning ratio of the drug administered by IN 
route compared to that after IV injection and can be calculated according to the 
following equation (Eq. 2):  
      (Eq. 2) 
where AUCbrain and AUCplasma are the areas under the drug concentration-time curves 
for brain and plasma after both IN and IV administration to mice. It is assured that 
preferential transport of drug to the brain occurs when DTE index is greater than 1 
(Wang et al., 2003). 
With the aim of evaluating the distribution of carbamazepine to specific brain 
regions (olfactory bulb, frontal cortex and the remaining portion of the brain) after its 
IN and IV administration, the drug concentrations in each specimen were determined at 
predefined time points (n = 4). The corresponding tissue-to-plasma and tissue-to-
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remaining portion of the brain carbamazepine concentration ratios were calculated and 
compared.  
 
2.9. Statistical analysis 
The data were expressed as mean ± standard error of the mean (SEM). Statistical 
comparisons between IN and IV administration groups were performed using unpaired 
two-tailed Student’s t-test. Differences were considered statistically significant for a p-
value lower than 0.05 (p < 0.05). 
 
3. Results 
3.1. Pharmacokinetics of carbamazepine after IN and IV administration 
The mean plasma, brain and liver concentration-time profiles of carbamazepine 
and carbamazepine-10,11-epoxide obtained in mice after a single dose of the 
carbamazepine (0.4 mg/kg) administered as nasal gel and IV solution are depicted in 
Figure 2. The corresponding main pharmacokinetic parameters estimated by non-
compartmental analysis are summarized in Table 2. It is noteworthy that, in all the three 
biological matrices, the pharmacokinetic profiles obtained after IN and IV 
administration are fairly comparable. As expected, the Cmax of the parent drug 
(carbamazepine) was attained almost instantaneously (5 min) after IV administration, 
and it occurred not only in plasma but also in brain and liver tissues. In comparison to 
IV delivery, only a slight delay in the time to reach the Cmax of carbamazepine (tmax = 10 
min) was observed for IN administration. Particularly interesting is the resemblance 
found in the magnitude of the peak concentrations of carbamazepine achieved in brain 
and plasma via IN and IV delivery. After reaching the Cmax, carbamazepine 
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concentrations in plasma, brain and liver decreased similarly following the two 
administration routes. As shown in Table 2, the extent of systemic and brain exposure to 
carbamazepine was also comparable after either IN or IV administration (as assessed by 
AUCt and AUCinf), whereas the extent of hepatic exposure to carbamazepine was 1.4-
fold greater after IV injection (as assessed by AUCt). Thus, the absolute bioavailability 
estimated for carbamazepine delivered via the IN route was found to be very high 
(107.64%), indicating that a comparable amount of the drug was easily and rapidly 
accessible in the systemic circulation following both IN and IV administrations. 
Regarding the MRT parameter presented in Table 2, it can be noted that higher values 
were attained for plasma and brain after IN administration comparatively to IV 
administration, in contrast with the liver, where the highest MRT value was assigned to 
the IV route.  The DTE index calculated for IN delivery of carbamazepine was 0.98 
which did not provide any discriminative information of the potential for direct nose-to-
brain transport of the drug via IN route. In opposition, the estimated DTE value appears 
to suggest that the uptake of carbamazepine into the CNS through the nasal cavity is 
predominately achieved by crossing the BBB after a quick nasal absorption of the drug 
to the systemic blood. Therefore, taking into account these pharmacokinetic data, the 
impact of the direct nose-to-brain delivery of carbamazepine after IN instillation was 
not evident when considering only the analysis of whole brain homogenate 
concentrations.   
The concentrations of carbamazepine-10,11-epoxide were also simultaneously 
determined in the referred matrices. Overall, the carbamazepine-10,11-epoxide levels 
were near or below the limit of quantification of the analytical method, thus the 
estimation of the corresponding pharmacokinetic parameters was limited and therefore 
their values are not very informative (Table 2). 
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3.2. Brain biodistribution of carbamazepine after IN and IV administration 
 To achieve more specific and informative data on the rostral-caudal brain 
biodistribution of carbamazepine following its IN and IV administration (0.4 mg/kg) to 
mice, some particular brain regions (olfactory bulb, frontal cortex and the remaining 
portion of the brain) were analysed as well as the plasma samples taken at the 
corresponding sampling time points. The mean concentrations of carbamazepine in 
plasma, olfactory bulb, frontal cortex and the remaining portion of the brain up to 60 
min post-dosing are presented in Figure 3. Accordingly, carbamazepine concentrations 
attained in plasma and in the different brain regions after IV administration of 
carbamazepine solution were very similar, assuming a homogenous brain distribution 
pattern. In contrast, following IN administration of carbamazepine nasal gel, different 
drug concentrations were observed throughout the specific brain regions analysed. 
Indeed, at 10 min post-dosing, higher carbamazepine concentrations were determined in 
the olfactory bulb (3.16 ± 0.09 µg/g) and frontal cortex (3.05 ± 0.09 µg/g) homogenates 
comparatively to the remaining portion of the brain (2.58 ± 0.09 µg/g), showing an 
uneven distribution of the drug from rostral to more caudal brain areas (Figure 3). 
Interestingly, this heterogeneous brain distribution of carbamazepine is more evident 
during the first three time points (5, 10 and 15 min) after the IN instillation, whereas a 
more uniform diffusion was accomplished from the 30 min onwards. In fact, it is 
noteworthy that, up to the 15 min, the highest concentrations of carbamazepine after IN 
administration were always found in the olfactory bulb in comparison to plasma, frontal 
cortex and remaining portion of the brain, sustaining a direct passage of the drug from 
nose to the brain. 
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The tissue-to-plasma and tissue-to-remaining portion of the brain concentration 
ratios were calculated for the olfactory bulb and frontal cortex specimens following both 
routes of administration (Table 3). After IV injection, similar ratios were observed at all 
sampling time points within the first hour post dosing, while after IN administration, 
discrepant values were ascertained, mainly up to 15 min. These results support the 
hypothesis that a direct transfer of carbamazepine from nose to the brain may be 
involved. Focusing particularly on the olfactory bulb-to-remaining portion of the brain 
ratios, it can be inferred that a direct nose-to-brain transport of carbamazepine occurs 
and probably via the olfactory pathway since the value of 1.29 ± 0.05 found at 5 min 
after IN delivery is significantly higher (p < 0.05) than that achieved after IV injection 
(0.95 ± 0.07) (Table 3).  
 
4. Discussion  
 It is estimated that more than 98% of all small molecules and nearly 100% of 
large molecular weight drugs systemically delivered to the CNS, either by oral or IV 
routes, do not readily cross the BBB and reach the brain parenchyma at 
pharmacologically active concentrations (Pardridge, 2005). As a consequence, many 
promising therapeutic agents may have been discarded due to its inability to effectively 
permeate BBB and others are given at high systemic doses to attain therapeutic levels at 
the biophase, which commonly lead to undesirable peripheral adverse effects and drug 
interactions.  
 In the light of the current knowledge, drug transport across the nasal mucosa into 
the CNS depends on a variety of factors that can range from the physicochemical 
properties of the drug to the formulation design and physiological conditions at the 
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absorption site (Pires et al., 2009; Vyas et al., 2006). Aware that nasal mucociliary 
clearance is one of the major limitations for nasal drug delivery (Marttin et al., 1998), 
the choice of a convenient nasal dosage form that avoids the rapid nasal drainage and 
promotes the increase of drug residence time within the nasal cavity is fundamental 
(Majithiya et al., 2006). Therefore, in order to avoid a fast mucociliary clearance of the 
drug but simultaneously keeping an easy administration form, a thermoreversible 
mucoadhesive gel composed by 18% Pluronic F-127 and 0.2% Carbopol 974P was 
herein selected to incorporate and deliver carbamazepine by the IN route since, 
according to the results reported by Badgujar et al. (2010), the viscous properties of  this 
formulation offer an appropriate and promising compromise between in situ gelling and 
ease of administration. Being a liquid-like solution at room temperature but changing to 
a firm gel at the physiological temperature within the nasal cavity (32-35°C) (Badgujar 
et al., 2010), in situ thermoreversible mucoadhesive gel displays a huge advantage over 
the conventional and more viscous hydrogels (Barakat et al., 2006; Czapp et al., 2008) 
concerning not only the ease of handling but also the accuracy of dosing (Basu and 
Bandyopadhyay, 2010).  
 Although carbamazepine is only currently available in oral dosage forms, it seems that 
the use of the IV route as a control is the most appropriate for this study. Indeed, due to the 
direct delivery of the drugs to the systemic circulation, IV administration will be responsible for 
the highest systemic exposure by comparison with any other route, creating appropriate 
conditions to allow a less variable drug incorporation and biodistribution. Moreover, 
considering that after IN administration drugs reach the CNS either via systemic circulation or 
olfactory epithelium, the contribution of the blood-mediated drug delivery to the brain can be 
inferred by employing IV injection and, consequently, the fraction of the drug directly 
transported from nose to brain could be more accurately discriminated. 
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 The pharmacokinetic results herein described revealed that, similarly to what 
happens following IV injection, the IN administration of carbamazepine nasal gel 
brought a rapid and extensive systemic absorption of the drug (assessed by Cmax, tmax, 
AUCt and AUCinf). The high carbamazepine concentrations attained in plasma after IN 
instillation, as well as the almost parallel time course of plasma and brain 
concentrations, clearly indicate that a substantial fraction of the drug has effectively 
been absorbed to the systemic circulation and reached the brain parenchymal tissue by 
crossing the BBB. In addition, comparable parent drug plasma concentration-time 
profiles following IN and IV administrations were also observed, supporting a similar 
bioavailability value (107.64%) achieved for the IN delivery of carbamazepine. These 
findings could be explained on the basis of the high lipophilic nature of the drug which 
log P value is 2.45. Indeed, small lipophilic molecules nasally administered can be 
rapidly absorbed to the blood stream by easily crossing the nasal membrane via 
transcellular diffusion and then enter into the brain after traversing the BBB. 
Experimental data reported in other research studies using both low molecular weight 
and lipophilic compounds such as diazepam (log P = 2.8) (Kaur and Kim, 2008), 
phenobarbital (log P = 1.47) (Czapp et al., 2008), NXX-066 (log P = 4.35) (Dahlin and 
Björk, 2001), progesterone (log P = 4.03) and estradiol (log P = 3.51) (van den Berg et 
al., 2004) underscored the fact that IN drug delivery occurred predominantly via the 
systemic pathway. The higher MRT values observed for plasma and brain on one hand 
and the lower MRT value attained in liver after IN administration comparatively to IV 
injection on the other hand, could also underlie the high bioavailability achieved for 
carbamazepine delivered by the IN route (Table 2). In fact, according to these results, 
the carbamazepine molecules stayed for a longer time in plasma and brain after IN 
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instillation in comparison with the IV injection, which in turn led to a greater retention 
of the drug in the liver.      
 Apart from the indirect pathway via the systemic circulation, it is believed that, 
there are two other different pathways by which a drug administered through the IN 
route may reach the CNS: the olfactory and the trigeminal neuronal routes (Dhuria et 
al., 2010). Although both of them provide a direct nose-to-brain delivery of the drug, 
the uptake via the olfactory neurons affords a preferential drug delivery to the olfactory 
bulb and rostral portion of the brain while the transference via the trigeminal nerve 
generally yields a more distant drug distribution to caudal brain areas. Thus, aiming at 
evaluating whether a direct transport of carbamazepine was occurring from the nose to 
the brain, the drug distribution in different brain regions was characterized after IN and 
IV administration. Interestingly, distinct distribution of carbamazepine through plasma, 
olfactory bulb, frontal cortex and remaining portion of the brain following IN and IV 
administration were herein reported for the first time. While a homogeneous brain 
distribution was observed for carbamazepine after IV injection, in the case of IN 
administration, the carbamazepine concentrations were different according to the 
respective brain area, presenting higher values in the rostral portion comparatively to 
the cerebral caudal region. Given that the carbamazepine brain concentration ratios 
determined at 5 min were 1.36-fold higher in the olfactory bulb and 1.22-fold higher in 
the frontal cortex employing the nasal delivery route than those obtained for IV 
injection (Table 3), it seems probable that a direct transport of the drug from nose to 
brain may be involved and that it occurred preferentially via the olfactory neuronal 
pathway. These findings assume particular interest in the field of the pharmacoresistant 
epilepsy. Indeed, it is nowadays scientifically accepted that the over-expression and/or 
up-regulation of multidrug efflux transporters in the BBB is one of the main 
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mechanisms responsible for the development of resistance to the antiepileptic drugs 
(Kwan et al., 2011; Löscher and Potschka, 2002; Remy and Beck, 2006). Overall, these 
transmembrane proteins pump the antiepileptic drugs back to the systemic circulation, 
restricting their access to the brain (Löscher and Potschka, 2002; Luna-Tortós et al., 
2008). In this context, the results herein obtained, demonstrate that the IN route may be 
considered as a novel approach to overcome the pharmacoresistance phenomena since a 
direct delivery of carbamazepine from nose to brain was clearly evidenced and it 
occurred in a considerable extent. 
Pooling the data derived from the pharmacokinetic and brain biodistribution 
studies following IN administration, it seems that with the high plasma concentrations 
on one hand and the superior delivery to the rostral regions of the brain on the other 
hand, carbamazepine reached the CNS through a combination of routes. Even though it 
is not possible to accurately quantify the contribution of each of these routes, we 
presume that a small fraction of the drug is in fact delivered to the brain via the 
olfactory pathway, while the most representative amount is still attributable to the 
systemic circulation. The 0.98 value obtained for the DTE index also strengthens this 
hypothesis. Notwithstanding, a further optimization of the carbamazepine nasal 
formulation will probably contribute to a better exploitation of the maximum potential 
that the IN route has to offer. 
In summary, IN delivery seems to represent a suitable and promising alternative 
route for the carbamazepine administration regarding not only its use on the chronic 
treatment of epilepsy but also in the case of more severe and acute emergency 
situations, such as status epilepticus. Indeed, the IN administration of carbamazepine 
allowed extensive plasma and brain exposures to the drug as well as a fast and 
pronounced drug uptake in the brain. Apart from being very practical and adequate to be 
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used outside the hospital setting, the uneven biodistribution pattern with the highest 
CBZ concentration levels attained in the rostral areas of the brain, strengthens the 
potential of IN delivery to be employed in acute convulsive emergencies.         
From the pharmacokinetic point of view, IN and IV administration of 
carbamazepine exhibited similar concentration-time profiles which probably point out 
to very similar pharmacological responses. In order to foresee whether IN delivery of 
carbamazepine could became clinically relevant, technological optimization of the nasal 
drug formulation, as well as further pre-clinical investigations are needed to evaluate the 
therapeutic efficacy attained via this route.  
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Figure captions 
Figure 1 – Chemical structures of carbamazepine (CBZ) and its main active metabolite, 
carbamazepine-10,11-epoxide (CBZ-E). 
Figure 2 – Concentration-time profiles of carbamazepine (CBZ) and carbamazepine-
10,11-epoxide (CBZ-E) in (A) plasma, (B) brain and (C) liver tissues following 
intranasal thermoreversible gel and intravenous solution administration of 
carbamazepine (0.4 mg/kg) to mice. Symbols represent the mean values ± SEM of four 
determinations per time point (n = 4). 
Figure 3 – Carbamazepine concentrations (mean ± SEM) up to 60 min post-dosing in 
plasma and different brain regions (olfactory bulb, frontal cortex and the remaining 
portion of the brain) after intranasal thermoreversible gel and intravenous solution 
administration of carbamazepine (0.4 mg/kg) to mice (n = 4, at each time point).  
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Table 1 – Validation parameters of the HPLC method employed for the quantification 
of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZ-E) in plasma, brain, 
liver, olfactory bulb and frontal cortex homogenate supernatants (n = 3).  
Drug Validation parameters Plasma Brain Liver 
Olfactory 
Bulbb 
Frontal 
Cortexb 
 Calibration  range (µg/mL) 0.1-30 0.1-15 0.2-20 0.02-4 0.05-7.5 
 Coefficient of determination (r2) 0.999 0.997 0.999 0.998 0.997 
CBZ LOQ (µg/mL) 0.1 0.1 0.2 0.02 0.05 
 Precision (%CV)a ≤ 6.67 ≤ 7.89 ≤ 3.92 ≤ 5.39 ≤ 7.89 
 Accuracy (%Bias)a -0.66-2.25 -5.41-3.75 0.28-1.55 -1.28-5.98 -5.41-3.75 
 Calibration  range (µg/mL) 0.4-30 0.05-15 0.2-20 - - 
 Coefficient of determination (r2) 0.999 0.996 0.999 - - 
CBZ-E LOQ (µg/mL) 0.4 0.05 0.2 - - 
 Precision (%CV)a ≤ 5.08 ≤ 4.48 ≤ 5.82 - - 
 Accuracy (%Bias)a 0.54-5.24 -6.04-4.34 -3.41-9.18 - - 
a Inter-day values, n = 3; b Calibration range and LOQ are expressed in µg; Bias, 
deviation from nominal value; CV, Coefficient of variation; LOQ, Limit of 
quantification. 
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Table 2 – Pharmacokinetic parameters of carbamazepine (CBZ) and carbamazepine-
10,11-epoxide (CBZ-E) following the administration of carbamazepine (0.4 mg/kg) to 
mice through intranasal (IN) thermoreversible gel and intravenous (IV) solution.   
Drug 
Pharmacokinetic 
parametersa 
Plasma  Brain  Liver 
IN IV  IN IV  IN IV 
CBZ 
tmax (min) 10.0 5.0  10.0 5.0  10.0 5.0 
Cmax (µg/mL) 2.32 2.47  2.14* 2.39*  2.78* 3.39* 
AUCt (µg.min/mL) 252.58 238.65  193.19# 185.71#  204.15# 288.88# 
AUCinf (µg.min/mL) 262.46 243.84  220.58# NC  NC 304.33# 
AUCextrap (%) 3.76 2.13  12.4 NC  NC 5.07 
kel (min-1) 0.013 0.027  0.010 0.006  0.006 0.019 
t1/2el (min) 55.2 25.3  70.8 127.1  112.1 35.7 
MRT (min) 76.1 64.9  71.0 52.9  53.1 64.2 
F (%)b 107.64 -  - -  - - 
CBZ-E 
tmax (min) 120.0 NA  NA NA  120.0 90.0 
Cmax (µg/mL) 0.60 NA  NA NA  0.63* 0.48* 
AUCt (µg.min/mL) 45.99 NA  NA NA  122.87# 50.40# 
AUCinf (µg.min/mL) NC NC  NC NC  NC NC 
AUCextrap (%) NC NC  NC NC  NC NC 
kel (min-1) NC NC  NC NC  NC NC 
t1/2el (min) NC NC  NC NC  NC NC 
MRT (min) NC NC  NC NC  NC NC 
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a Parameters were estimated using the mean concentration-time profiles obtained from 
four different animals per time point (n = 4). b Absolute intranasal bioavailability (F) 
was calculated based on AUCinf values; * Values expressed in µg/g; # Values expressed 
in µg.min/g; AUCextrap, Extrapolated area under the drug concentration time-curve; AUCinf, 
Area under the concentration time-curve from time zero to infinite; AUCt, Area under the 
concentration time-curve from time zero to the last quantifiable drug concentration; 
Cmax, Maximum peak concentration; kel, Apparent elimination rate constant; MRT, Mean 
residence time; NA, not available; NC, not calculated; t1/2el, Apparent terminal elimination 
half-life; tmax, Time to achieve the maximum peak concentration. 
 
 
Table 3 – Tissue-to-plasma and tissue-to-remaining portion of the brain concentration ratios of 
carbamazepine in different brain regions following intranasal and intravenous administration to 
mice (0.4 mg/kg). 
 
 
Concentration 
Ratios 
Intranasal  Intravenous        
 Post-
dosing 
time  
 Post-dosing 
time 
       
 5 min 10 
min 
15 min 30 
min 
60 
min 
5 
min 
10 
min 
15 
min 
30 
min 
60 
min 
Remaining 0.76 ± 0.91 0.82 ± 0.90 0.99 1.08 1.03 1.19 1.08 1.01 
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Brain Portion 
/ Plasma 
0.04* ± 
0.06 
0.07* ± 
0.03* 
± 
0.07 
± 
0.02 
± 
0.03 
± 
0.07 
± 
0.02 
± 
0.02 
Frontal 
Cortex / 
Plasma 
0.88 ± 
0.05* 
1.08 
± 
0.04 
1.01 ± 0.03 0.83 
± 
0.05* 
0.97 
± 
0.06 
1.04 
± 
0.02 
1.01 
± 
0.03 
1.11 
± 
0.08 
1.09 
± 
0.02 
1.03 
± 
0.02 
Olfactory 
Bulb / Plasma 
0.98 ± 
0.04 
1.11 
± 
0.03 
1.03 ± 0.04 0.87 
± 
0.04* 
0.99 
± 
0.06 
1.03 
± 
0.09 
0.97 
± 
0.06 
1.12 
± 
0.11 
1.04 
± 
0.05 
0.84 
± 
0.08 
Frontal 
Cortex / 
Remaining 
Brain Portion 
1.17 ± 
0.05* 
1.19 
± 
0.05* 
1.25 ± 
0.09* 
0.92 
± 
0.03 
0.98 
± 
0.02 
0.96 
± 
0.02 
0.98 
± 
0.02 
0.94 
± 
0.05 
1.01 
± 
0.03 
1.02 
± 
0.02 
Olfactory 
Bulb / 
Remaining 
Brain Portion 
1.29 ± 
0.05* 
1.23 
± 
0.07* 
1.28 ± 
0.06* 
0.96 
± 
0.02 
1.00 
± 
0.03 
0.95 
± 
0.07 
0.94 
± 
0.04 
0.94 
± 
0.07 
0.96 
± 
0.03 
0.83 
± 
0.08 
Data are expressed as the mean values ± standard error of the mean (SEM) of four 
animal determinations (n = 4). Statistically significant differences (p < 0.05) between 
the two routes of administration (intranasal versus intravenous) are marked with an 
asterisk (*). 
 
 
